Covalon Technologies Ltd.
Covalon Technologies Ltd. (COV.V) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cov.v · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Covalon Technologies Ltd.You COV.V | $60M | 36.34x | — | $0.06 |
 Arch Biopartners Inc. ARCH.V | $33M | N/A | — | -$0.02 |
 Cannabix Technologies Inc. BLO.CN | $75M | N/A | — | -$0.04 |
 C21 Investments Inc. CXXI.CN | $48M | N/A | — | -$0.03 |
 Defence Therapeutics Inc. DTC.CN | $29M | N/A | — | -$0.07 |
 1CM Inc. EPIC.CN | $19M | 57.07x | — | $0.00 |
 iAnthus Capital Holdings, Inc. IAN.CN | $35M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Covalon Technologies Ltd. (COV.V) measures how much investors pay for each dollar of the company's trailing earnings. COV.V's current PE ratio of 36.34x is calculated by dividing its stock price of $2.16 by its TTM earnings per share of $0.06.
Frequently asked questions
COV.V pe ratio · 6 questionsCOV.V's current PE ratio is 36.34x as of 2026-06-09, based on a stock price of $2.16 and TTM EPS of $0.06. Data sourced from Financial Modeling Prep via COV.V's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Covalon Technologies Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09